Latest News
These are CLL Ireland’s latest news posts from Facebook – but make sure to visit our CLL Ireland Facebook page for older posts.
www.facebook.com/MDAnderson/videos/396120231170919/
MD Anderson Cancer Center
CAR T-cell therapy is changing the way we treat adults with B-cell lymphoma and children and young adults with acute lymphoblastic leukemia.
Watch our Dr. William Wierda explain how this cutting-edge immunotherapy works. #endcancer
Congratulations to all those who worked so hard on patients behalf to secure the approval of Venetoclax and rituximab for patients in England and Wales who have failed chemotherapy with relapsed or refractory #CLL
We look on in hope that this approval will follow for patients on the island of Ireland
www.nice.org.uk/news/article/thousands-of-adults-with-chronic-lymphocytic-leukaemia-to-benefit-fr...
Thousands of adults with chronic lymphocytic leukaemia to benefit from new treatment option
nice.org.uk
18 January 2019 Share Share Linked In Twitter Facebook Email More... Thousands of adults with chronic lymphocytic leukaemia to benefit from new treatment option Thousands of people will benefit as NICE recommends venetoclax with rituximab for adults with relapsed or refractory chronic lymphocytic le...Dr. Davids discusses the research undertaken with Brian Koffman and the CLL Society Inc.exploring how patients with #CLL make therapy decisions. Recently presented at #ASH18, the results suggested patients want involvement in their therapy decisions | via Journal of Clinical Pathways ow.ly/49Ov30nlL81
journalofclinicalpathways.com
Interviews Understanding Factors That Influence Treatment Decision-Making in Patients With CLL January 15, 2019 JCP Editors Journal of Clinical Pathways spoke with Matthew S Davids, MD, MMSc, Department of Medical Oncology, Dana-Farber Cancer Institute (Boston, MA), regarding a presentation at the A...Ibrutinib & Other Options for CLL
This short video is part of a series reviewing a #CLL patient who relapsed after being treated with frontline #ibrutinib, and considers the various mono- & combination treatment options for this setting | via Targeted Oncology
ow.ly/PJd130nhPZY
Ibrutinib and Other Options for CLL
targetedonc.com
Therapy options for patients with chronic lymphocytic leukemia in conjunction with treatment parameters, namely the use of frontline ibrutinib.Dr. Jeff Sharman summarises results of recent studies as presented at #ASH18 & how the results of these #clinicaltrials will impact first-line management of chronic lymphocytic leukemia #CLL | via Healio.com ow.ly/RJF930nhQzs
VIDEO: Recent trials impact first-line management of chronic lymphocytic leukemia
healio.com
SAN DIEGO — In this video, Jeff Sharman, MD, medical director for hematology research at the U.S. Oncology Network and director of research at Willamette Valley Cancer Institute in Oregon, reviews top-line data on chronic lymphocytic leukemia that was presented at the ASH Annual Meeting and Ex...Exciting results from study on the future of dose-limited regimens in #CLL were recently presented at #ASH18.
67% of previously untreated & 50% R/R patients attained MRD-negative response (No leukaemia in BOTH blood & bone marrow) | via Targeted Oncology
ow.ly/qU5e30ni7N4
Expert Discusses Promising Findings With Ibrutinib, Venetoclax, and Obinutuzumab in CLL
targetedonc.com
Kerry A. Rogers, MD, discusses phase II findings with obinutuzumab, ibrutinib, and venetoclax and the future of dose-limited regimens in CLL.A recent study found that physicians tended to under-report fatigue for immune thrombocytopenia (ITP) patients in comparison to self-reporting from patients | via Patient Worthy
ow.ly/AsJy30nhPhE
Study Finds That Immune Thrombocytopenia Patients Don't See Eye to Eye on Fatigue - Patient Worthy
patientworthy.com
Don't miss this story about the latest immune thrombocytopenia research.Prof. John Gribben provides an overview of key updates in treatment for #CLL including the ECOG, MURANO and iLLUMINATE studies from #clinicaltrials investigating #ibrutinib vs. FCR standard #chemoimmunotherapy filmed at #ASH18 | via VJHemOnc
ow.ly/ATjd30ngTuC
CLL updates from ASH 2018: ibrutinib is the treatment of choice
vjhemonc.com
John Gribben, MD, DSc, FRCP, FRCPath, FMed Sci, of the Barts Cancer Institute, London, UK, provides an overview of key updates in treatment for chronic lymphocytic leukemia (CLL), specifically the ECOG-E1912 (NCT02048813), MURANO (NCT02005471), and iLLUMINATE (NCT02264574) studies investigating ibru...Prof. Chris Fegan and Prof. Anna Schuh discuss some of the key #CLL information presented at the recently held #ASH18 conference. We're thankful to Leukaemia Care for facilitating this useful synopsis for patients.
ow.ly/Jfec30ngBNzWe were delighted to be able to film Professor Chris Fegan (Cardiff, UK) and Professor Anna Schuh (Oxford, UK) about all the CLL information which was presen...
m.youtube.com/watch?v=6nOKjGbGJtkIn the context of therapeutic management of chronic lymphocytic leukemia (CLL), Nicole Lamanna, M.D., offers advice regarding lifestyle modifications that ma...
